title: Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells.
abstract: In this work the selective uptake of native horse spleen ferritin and apoferritin loaded with MRI contrast agents has been assessed in human breast cancer cells (MCF-7 and MDA-MB-231). The higher expression of L-ferritin receptors (SCARA5) led to an enhanced uptake in MCF-7 as shown in T2 and T1 weighted MR images, respectively. The high efficiency of ferritin internalization in MCF-7 has been exploited for the simultaneous delivery of curcumin, a natural therapeutic molecule endowed with antineoplastic and anti-inflammatory action, and the MRI contrast agent Gd-HPDO3A. This theranostic system is able to treat selectively breast cancer cells over-expressing ferritin receptors. By entrapping in apoferritin both Gd-HPDO3A and curcumin, it was possible to deliver a therapeutic dose of 167 μg ml(-1) (as calculated by MRI) of this natural drug to MCF-7 cells, thus obtaining a significant reduction of cell proliferation.
authors: University of Turin, Department of Molecular Biotechnology and Health Sciences, via Nizza 52, Torino, Italy. simonetta.geninatti@unito.it.
authors: S
authors: S
authors: Geninatti Crich
authors: M
authors: M
authors: Cadenazzi
authors: S
authors: S
authors: Lanzardo
authors: L
authors: L
authors: Conti
authors: R
authors: R
authors: Ruiu
authors: D
authors: D
authors: Alberti
authors: F
authors: F
authors: Cavallo
authors: J C
authors: JC
authors: Cutrin
authors: S
authors: S
authors: Aime
mesh_terms: D000362:Agar / Q000737:chemistry; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001052:Apoferritins / Q000737:chemistry; D001943:Breast Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003287:Contrast Media / Q000737:chemistry; D003474:Curcumin / Q000737:chemistry; D004337:Drug Carriers; D005260:Female; D005293:Ferritins / Q000737:chemistry; D006736:Horses; D006801:Humans; D033862:Iron-Binding Proteins / Q000737:chemistry*; D061986:MCF-7 Cells; D008279:Magnetic Resonance Imaging; D011956:Receptors, Cell Surface / Q000737:chemistry*; D051117:Scavenger Receptors, Class A / Q000378:metabolism; D013154:Spleen / Q000378:metabolism; D013696:Temperature; D000068936:Theranostic Nanomedicine
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D003287:Contrast Media; D004337:Drug Carriers; D033862:Iron-Binding Proteins; D011956:Receptors, Cell Surface; C569833:SCARA5 protein, human; D051117:Scavenger Receptors, Class A; C027293:ferritin receptor; D000362:Agar; D005293:Ferritins; D001052:Apoferritins; D003474:Curcumin